An online semaglutide prescription begins with telehealth care, not a store checkout. A licensed clinician must evaluate the patient, decide whether any prescription is appropriate, and document that decision. A prescription is never guaranteed.
This page is general information, not medical advice. Talk to a licensed clinician about your situation.
This site is an informational and pricing overview. It takes no payment, collects no protected health information, and runs no intake form. All checkout and intake happens on joinbodygood.com/intake.
What a sound online process includes
The process should identify the clinician and confirm that the clinician is licensed to treat patients in your state. It should collect a meaningful health history, including current medicines, allergies, past conditions, and relevant symptoms. A form can organize that information, but a form does not make the prescribing decision.
The clinician reviews the information, asks follow-up questions when needed, and considers risks, potential benefits, and alternatives. The clinician may request records or laboratory work when clinically appropriate. The answer may be a prescription, a different care plan, an in-person referral, or no prescription.
If a prescription is issued, it goes to a pharmacy that can lawfully dispense it. You should know the exact product prescribed, which pharmacy will fill it, what costs are separate, and how to contact the clinical team after the visit.
FDA's BeSafeRx resources explain warning signs for unsafe online pharmacy activity. An offer to sell prescription medication without a valid prescription or adequate clinical evaluation is a reason to stop.
FDA-approved prescription products
Semaglutide is the active ingredient in two distinct FDA-approved Novo Nordisk products, Ozempic and Wegovy. They have different approved uses and product labeling. The presence of the same active ingredient does not erase those differences. A clinician must select a product and care plan based on the patient's circumstances.
Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. They are included in the safety summary because this page later distinguishes compounded medication from all four branded products.
Important safety information: Ozempic, Wegovy, Mounjaro, and Zepbound carry boxed warnings about the risk of thyroid C-cell tumors. They are contraindicated in people with a personal or family history of medullary thyroid carcinoma, or MTC, and in people with Multiple Endocrine Neoplasia syndrome type 2, or MEN 2. Major risks described across their official Prescribing Information and Medication Guides include pancreatitis, gallbladder problems, acute kidney injury related to dehydration, severe gastrointestinal reactions, serious allergic reactions, and low blood sugar when used with certain diabetes medicines. Some labels include additional risks, including diabetic retinopathy complications. Common side effects can include nausea, vomiting, diarrhea, constipation, and abdominal pain. Read each linked manufacturer document for complete approved uses, boxed warnings, contraindications, risks, side effects, and patient instructions.
Approved products are dispensed pursuant to a valid prescription. Pharmacy price and insurance cost sharing depend on the product, pharmacy, and plan. Coverage is never assured, and a plan makes its own approval and payment decisions.
Compounded prescription products
Compounded semaglutide is a separate category from the FDA-approved products discussed above.
Compounded medications are not FDA-approved. FDA does not review them for safety, effectiveness, or manufacturing quality.
Compounded semaglutide is not Zepbound, Mounjaro, Ozempic, or Wegovy. It is not a generic or interchangeable version of any approved drug. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S.
Compounded medications may be dispensed only pursuant to a valid prescription issued by a licensed clinician after a clinical evaluation, from a state-licensed pharmacy. The prescription should identify what is being prescribed. The dispensing pharmacy should provide labeling, storage directions, and a way to reach a pharmacist.
FDA provides general information about the category in its overview of human drug compounding. Patients should ask direct questions and understand that the regulatory review described for approved finished products does not apply to compounded medications.
Questions to ask a telehealth service
Before sharing health information or paying a fee, ask:
- Is the evaluating clinician licensed in my state?
- Will I have a real clinical review and a way to ask follow-up questions?
- Will you clearly identify whether a proposed product is FDA-approved or compounded?
- Which state-licensed pharmacy would dispense a prescription?
- What does the clinical service fee cover?
- What medication, laboratory, or shipping costs are billed separately?
Clear answers help distinguish a clinical service from a simple product pitch. Avoid a service that hides the pharmacy, promises a prescription, or describes every applicant as eligible.
Body Good's role and fees
Body Good provides a clinical service. Its prices are Body Good service fees for the program described during intake. They are not medication prices and are not a quote for any individual. Medication cost is separate and is not included. Eligibility is determined by a clinician.
The program may include the evaluation and follow-up support described during intake. If coverage support is part of a selected service, that means assistance with benefits information and plan-requested paperwork. The plan determines approval and payment. Body Good cannot guarantee coverage or a prescription.
The pharmacy bills for medication. Outside laboratory services, if clinically appropriate, may also be billed separately. Ask for the time period each service fee covers and what happens if the clinician does not prescribe.
What happens after the evaluation
If the clinician determines a prescription is appropriate, the prescription is sent to a state-licensed pharmacy. The pharmacy reviews it, resolves questions with the prescriber, and dispenses according to applicable requirements. Pharmacy availability and price can change.
Follow-up matters. Tell the clinician about side effects, new medicines, or changes in health. Use only the product dispensed for you, follow its instructions, and do not adjust the dose without clinical guidance. Seek urgent medical help when instructed by the product labeling or your care team.
An online visit can make access to a clinician more convenient. It does not remove the safeguards of evaluation, prescribing, pharmacy dispensing, and ongoing care.
Frequently asked questions
Can a website guarantee a semaglutide prescription?
No. Only a licensed clinician who has completed a clinical evaluation can decide whether to prescribe. The clinician may determine that a prescription is not appropriate.
Is medication included in a Body Good service fee?
No. The Body Good price is a service fee for the program described during intake. Medication cost is separate and not included, and the pharmacy sets its charge.
Where does the Body Good process begin?
Begin Body Good's secure clinical intake. Completing intake does not guarantee eligibility, a prescription, coverage, or pharmacy availability.
Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. Body Good is not affiliated with, endorsed by, sponsored by, or authorized by Eli Lilly and Company or Novo Nordisk A/S. All trademarks are the property of their respective owners.